Evidence map›Paper›PMID 38015898›Full record

ArticlePloS one2023

selSeq: A method for the enrichment of non-polyadenylated RNAs including enhancer and long non-coding RNAs for sequencing.

Jason D Limberis, Alina Nalyvayko, Joel D Ernst, John Z Metcalfe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jason D LimberisDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States of America.ORCID 0000-0002-7893-8416
Alina NalyvaykoDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States of America.
Joel D ErnstDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States of America.
John Z MetcalfeDivision of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Centre, University of California, San Francisco, San Francisco, CA, United States of America.

Funding

Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosisR01AI153213 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David M Engelthaler, John Zapata Metcalfe · 2021 to 2026
$3.7M
A novel cartridge-based sequencing solution for decentralized M. tuberculosis resistance detectionR01AI177637 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Soumitesh Chakravorty, John Zapata Metcalfe · 2023 to 2026
$2.8M
NIAID NIH HHS R01 AI153213NIAID NIH HHS R01 AI177637
6 · The paper itself

Abstract

Non-polyadenylated RNA includes a large subset of crucial regulators of RNA expression and constitutes a substantial portion of the transcriptome, playing essential roles in gene regulation. For example, enhancer RNAs are long non-coding RNAs that perform enhancer-like functions, are bi-directionally transcribed, and usually lack polyA tails. This paper presents a novel method, selSeq, that selectively removes mRNA and pre-mRNA from samples enabling the selective sequencing of crucial regulatory elements, including non-polyadenylated RNAs such as long non-coding RNA, enhancer RNA, and non-canonical mRNA.

Indexed as

RNA, Long NoncodingGene Expression RegulationRNA, MessengerRNA PrecursorsTranscriptomeRNA, Long NoncodingRNA, MessengerRNA Precursors

Identifiers

PMID38015898
PMCPMC10684010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.